BSX Inhibitors
BSX inhibitors are a class of chemical compounds that play a crucial role in modulating specific cellular processes by targeting the BSX protein. BSX, or Brain-Specific Homeobox, is a transcription factor encoded by the BSX gene and primarily expressed in the developing central nervous system, particularly in the brain. BSX inhibitors are designed to interact with this protein, altering its activity and thereby influencing downstream gene expression and cellular functions.
BSX inhibitors can vary widely, encompassing a range of small molecules and peptides. These compounds typically possess a high affinity for BSX, allowing them to bind to the protein and interfere with its function. By binding to BSX, these inhibitors can either enhance or suppress its transcriptional activity, depending on the specific compound and the desired biological outcome. This modulation of BSX function can have far-reaching effects on neuronal development, neurogenesis, and other processes within the central nervous system, making BSX inhibitors valuable tools for research aimed at understanding the intricate molecular mechanisms that underlie brain development and function.
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
(±)-JQ1 | 1268524-69-1 | sc-472932 sc-472932A | 5 mg 25 mg | $231.00 $863.00 | 1 | |
Binds to the bromodomain and extra-terminal (BET) family of proteins, potentially altering BSX transcriptional activity by modifying chromatin accessibility. | ||||||
GSK 525762A | 1260907-17-2 | sc-490339 sc-490339A sc-490339B sc-490339C sc-490339D | 5 mg 10 mg 50 mg 100 mg 1 g | $300.00 $540.00 $940.00 $1680.00 $5900.00 | ||
Targets BET bromodomains, which could disrupt protein interactions necessary for BSX-mediated gene expression. | ||||||
4-[(1E)-2-(2-Amino-4-hydroxy-5-methylphenyl)diazenyl]-N-2-pyridinylbenzenesulfonamide | 1395084-25-9 | sc-480120 | 5 mg | $300.00 | ||
Inhibits BRD4, a member of the BET family, potentially influencing the transcriptional regulation of BSX target genes. | ||||||
PFI-1 | 1403764-72-6 | sc-478504 | 5 mg | $98.00 | ||
Selectively binds to BET bromodomains, which may interfere with BSX's role in transcriptional regulation. | ||||||
RVX 208 | 1044870-39-4 | sc-472700 | 10 mg | $340.00 | ||
Affects BET protein interactions and might alter the expression levels of genes regulated by BSX. | ||||||
(S)-2-(4-(4-Chlorophenyl)-2,3,9-trimethyl-6H-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepin-6-yl)-N-(4-hydroxyphenyl)acetamide | 202590-98-5 | sc-501130 | 2.5 mg | $330.00 | ||
Another BET bromodomain inhibitor that could modify the transcriptional network involving BSX. | ||||||
CPI-0610 | 1380087-89-7 | sc-507490 | 10 mg | $495.00 | ||
A BET bromodomain inhibitor that may impact BSX function by changing the chromatin state at BSX-responsive promoters. | ||||||
MS417 | 916489-36-6 | sc-507505 | 5 mg | $228.00 | ||
A BET protein antagonist that may disrupt the normal function of BSX by altering gene expression patterns. | ||||||